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Many epithelial cancers have been shown to overexpress the enzyme cyclooxygenase-2 
(COX-2), an enzyme responsible for both the metabolism of arachidonic acid (AA) to 
prostaglandins and arachidonoyl ethanolamine (AEA) to prostaglandin-ethanolamides 
(prostamides).  AEA has demonstrated cytotoxicity in COX-2 overexpressing cancers via its 
metabolism to the novel J-series prostamide, 15d-PMJ2. Using what is known about how AEA 
induces cell death, derivatives of AEA were synthesized to investigate COX-2 metabolism, PGDS 
metabolism, FAAH degradation resistance, and the inherent cytotoxicity of their J-series 
prostaglandin analogs. 
A structure-activity relationship study was conducted with ten AEA derivatives to 
determine what modifications to the ethanolamide moiety improve anti-cancer activity in COX-2 
overexpressing JWF2 tumorigenic keratinocytes and HCA-7 colorectal cancer cells.  Important 
cytotoxic characteristics of AEA and AEA analogs were identified from the SAR study.  Hydrogen 
bond accepting or donating ability seems to be the most important characteristic retained in 
 
cytotoxic AEA analogs.  Distance between the amide bond and terminal hydroxyl moiety seems 
to be important, but no trend as to whether a shorter or longer carbon chain is apparent.  Addition 
of an aryl group does not interfere with cytotoxicity and in fact improves it as long as a terminal 
hydroxyl group is retained. 
Two derivatives which displayed cytotoxicity similar to or greater than that of AEA, 
NAGly and arvanil, were selected for further studies exploring their cytotoxic and metabolic 
profiles.  Arvanil (LC50 = 6.03 µM) demonstrated greater cytotoxicity than NAGly (LC50 = 9.54 
µM) and our positive control AEA (LC50 = 9.39 µM).  Metabolism by COX-2 and PGDS to D-
series and J-series prostaglandin analogs were responsible for arvanil’s apoptotic anti-cancer 
activity.  The novel J-series prostamide analog, 15d-PMJ2-arvanil, was identified for the first time 
as well as another metabolite, possibly an A-series prostamide analog, with identical mass-to-
charge ratios and fragmentation patterns in the mass spectrum.  These molecules will be 
synthesized, and their anti-cancer activity investigated in future studies. Collectively, these results 
suggest that structural modification of the ethanolamide moiety of AEA provides a means for 
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CHAPTER ONE: INTRODUCTION 
 
1.1:  Cancer 
Cancer accounts for almost a quarter of all deaths in the United States annually.  Cancer is 
the global term for a disease with two characteristics, uncontrollable proliferation and metastasis 
of malignant cells (American Cancer Society, National Cancer Institute). Cancer is caused by 
genetic changes or mutations in DNA which normally control cell function, growth, division, and 
apoptosis or programmed cell death.  Cancer can initiate in any tissues of the body, but some forms 
of cancer are more common than others, such as non-melanoma skin cancer, or more deadly than 
others, such as melanoma or colorectal cancer. 
1.1.1:  Non-Melanoma Skin Cancer (NMSC) 
NMSC is the most commonly diagnosed cancer in the United States with an estimated two 
million cases each year (American Cancer Society).  The rate of incidence is due to environmental 
factors such as UV radiation as well as an increasing average age shift (Diffey and Langtry 2005, 
Kricker et al. 1995).  NMSC is not as deadly as melanoma, but there are still an estimated 2,000 
deaths attributed to NMSC every year in the United States (American Cancer Society).  NMSC 
puts a monetary strain on the health care system with an estimated cost of $4.8 billion per year 
(US Surgeon General, 2014).  Current treatments for NMSC include surgical removal, a costly but 
effective treatment, and topical treatment with 5-fluorouracil (5-FU), which produces severe 
adverse effects (Metterle et al. 2016).  Because of the prevalence of NMSC, there is a need for 
effective, convenient, and economical chemotherapeutic treatments (Guy and Ekwueme 2011). 
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1.1.2: Colorectal Cancer 
 Colorectal cancer is the third most commonly diagnosed cancer in the United States, behind 
only NMSC and melanoma skin cancer, with an estimated 145,000 new cases in the United States 
in 2019 (American Cancer Society).  Unlike NMSC, colorectal cancer is a deadly cancer and is 
expected to cause 50,000 deaths in 2019.  Evidence suggests colorectal cancer can be prevented 
by regular colonoscopy screening and removal of adenomatous polyps which progress to 
adenocarcinoma (Winawer et al. 1993).  Even with regular colonoscopy screenings, the incidence 
of colorectal cancer is on the rise due to the same age-related factors as NMSC as well as dietary 
factors.  Current treatments include surgical removal of the tumor or chemotherapy with FOLFOX 
(5-FU, leucovorin, and oxaliplatin), CapeOX (capecitabine and oxaliplatin), or Irinotecan (Schrag 
2004, American Cancer Society).  Unlike NMSC, chemotherapeutic treatments for colorectal 
cancer are systemic, leading to widespread side effects and tissue damage.  Because of the 
prevalence and mortality rate of colorectal cancer, there is a need for effective, convenient, and 
economical treatments.   
 
1.2: Cyclooxygenase-2 (COX-2) and Cancer 
The primary function of COX-2 is to synthesize polyunsaturated fatty acids called 
prostaglandins from the 20-carbon arachidonic acid (AA) (Scheme 1.1).  COX-2 also produces 
ethanolamide-conjugated prostaglandins (prostamides) from anandamide (AEA). There are 
several types of prostaglandins and prostaglandin-ethanolamides (prostamides) including E-series, 
F-series, and D-series.  These series of prostaglandins are distinguished by the substituents of the 
cyclopentane ring, specifically the placement of the hydroxyl or ketone substituents (Scheme 1.1).  
These lipids regulate diverse processes including inflammation, platelet function, and pain (Funk 
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2001, Matias et al. 2004). It has been also determined that prostaglandins play a prominent role in 
carcinogenesis.  Numerous studies have shown that COX-2 and its metabolic product, 
prostaglandin-E2 (PGE2), are overexpressed in many epithelial cancers including NMSC and colon 
cancer (Boukamp, P. 2005, Buckman et al. 1998, Armstrong and Kricker 2001).  PGE2 binding to 
E-type prostaglandin receptors activates a signal transduction cascade that leads to cancer cell 
proliferation (Fischer et. al 2000, Kiraly et al. 2016).  In contrast, both the inhibition of COX-2 
activity and the antagonism of EP receptors blocks epithelial tumor growth, particularly in NMSC 
and colorectal cancer (Sheng et al. 1997, Kiraly et al. 2016).  
D- and J-series prostaglandins are formed when AA is metabolized by COX-2 to PGH2.  
PGH2 is enzymatically converted by PGDS to PGD2 and PGD2 is spontaneously dehydrated to 
prostaglandin-J2 (PGJ2), ∆12.14-PGJ2, and 15-deoxy-∆12.14-PGJ2 (15d-PGJ2). Furthermore, we 
discovered that COX-2 also metabolizes AEA to the cytotoxic molecules prostamide-J2 (PMJ2), 
∆12.14-PMJ2, and 15-deoxy-∆12.14-PMJ2 (15d-PMJ2). D- and J-series prostaglandins and 
prostamides have demonstrated anti-proliferative effects on a variety of cancers (Van Dross et. al. 


















1.2.1: Mechanism of Arachidonic Acid Oxygenation by COX-2 
A series of radical reactions converts arachidonic acid to prostaglandin-G2 (PGG2) 
followed by reduction of PGG2 to prostaglandin-H2 (PGH2). This series of radical reactions is 
initiated by the removal of the 13-pro(S)-hydrogen of arachidonic acid by the tyrosyl radical of 
Tyr385 followed by the trapping of a pentadienyl radical by O2 at C-11 (Scheme 1.2, steps 1 and 
2) (Dietz et al. 1988).  This peroxyl radical then cyclizes at C-9 and the ensuing carbon-centered 
radical at C-8 cyclizes at C-12 resulting in an endoperoxide (Scheme 1.2, step 3). The resonance-
stabilized allylic radical at C-15 is trapped by O2 forming the 15-(S)-peroxyl radical which is then 
reduced by hydrogen atom abstraction from tyrosine to prostangladin-G2 (Scheme 1.2, steps 4 and 
5) (Hamberg and Samuelsson 1967). 
 







1.3: Endogenous Cannabinoid (Endocannabinoid) System 
The endocannabinoid system consists of endocannabinoids, which are lipid 
neurotransmitters, cannabinoid receptor 1 (CB1), cannabinoid receptor 2 (CB2), and enzymes 
responsible for the synthesis and inactivation of cannabinoid and endocannabinoid ligands (Di 
Marzo et al. 1994, Di Marzo et al. 2004, Bisogno et al. 2005, Di Marzo 2009). Endocannabinoids 
regulate pathological and physiological processes including inflammation, analgesia, learning, 
cancer, and appetite through the activation of the endocannabinoid system (Di Marzo et al. 2000, 
Bisogno et al. 2005).  This system was originally discovered due to investigation of the receptors 
responsible for the effects of the phytocannabinoid ∆9 tetrahydrocannabinol (∆9THC), the 
psychoactive ingredient of marijuana.  Endocannabinoids have the ability to promote tumor cell 
death by initiating growth arrest and apoptosis (Fowler et al. 2003, Linsalata et al. 2010).  These 
cytotoxic actions occur by both cannabinoid receptor dependent and independent pathways (Melck 
et al. 1999a, Melck et al. 2000, De Petrocellis et al. 1998, Grimaldi et al. 2006, Gustafsson et al. 
2009, Patsos et al. 2010, Alpini and Morrow. 2009, Brown et al. 2010, Van Dross et al. 2013, 
Soliman and Van Dross 2016b). 
1.3.1: Arachidonoyl Ethanolamine (Anandamide) (AEA) 
AEA was the first endocannabinoid discovered in the endocannabinoid system (Devane et 
al. 1992). To initiate its biological response, AEA binds to the cannabinoid receptors and then it is 
transported into the cells via the anandamide membrane transporter (AMT).  AEA is inactivated 
by fatty acid amide hydrolase (FAAH), an enzyme that converts AEA to AA and ethanolamine 
(Deutsch et al. 1993, Cravatt et al. 1996). 
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1.3.2: COX-2 Metabolism of AEA 
COX-2 not only metabolizes AA, but also its ethanolamine-conjugated counterpart AEA 
at a rate of metabolism 27% that of AA (Scheme 1.3) (Kozak et al. 2001, Kozak et al. 2002). AEA 
is an endocannabinoid produced in the brain, which plays a role in a variety of biological processes 
including pain, inflammation, depression, and pleasure. (Di Marzo 2009, Matias et al. 2004). In 
cancer cell lines that overexpress COX-2, AEA is cytotoxic (Di Marzo 2009, Soliman et al. 2016a).  
AEA is metabolized by COX-2 and then by PGE-synthase (PGES), PGD-synthase (PGDS), or 
PGF-synthase (PGFS) to prostamide-E2 (PME2), prostamide-D2 (PMD2), and prostamide-F2α 
(PMF2α) respectively (Matias et al. 2004). Prostamide-D2 (PMD2) is spontaneously dehydrated to 
prostamide-J2 (PMJ2) and Δ12,14-PMJ2, which are spontaneously dehydrated to 15-deoxy-Δ12,14-
PGJ2-EA (15d-PMJ2).  In previous studies we determined 15d-PMJ2 demonstrates selective 
toxicity via endoplasmic reticulum (ER) stress induced apoptosis in NMSC and melanoma in vitro 
as well as inducing potent tumor cell apoptosis in vivo (Ladin et al. 2017).  Selective toxicity is a 
crucial characteristic of 15d-PMJ2, which is a requirement for novel chemotherapeutics to reduce 
side effects. 






1.4: Fatty Acid Amide Hydrolase (FAAH) 
AEA is a known substrate for another enzyme, FAAH, a membrane protein belonging to 
the serine hydrolase family.  The hydrolase activity of FAAH regulates the biological responses 
of AEA by controlling its intracellular concentration (Cravatt et al. 1996, Deutsch et al. 1993, 
Bisogno et al. 1997, Bifulco et al. 2004, Siegmund et al. 2006). FAAH degrades AEA into AA and 
ethanolamine, and once degraded, AA is sequestered in the phospholipid membrane (Scheme 1.4).  
This knowledge can be used to design AEA derivatives that resist degradation by FAAH and 
thereby exhibit greater activity than AEA.  Specifically, we hypothesize that the addition of 
functional groups to AEA that inhibit its inactivation by FAAH will make more of the AEA analog 
created available for metabolism by COX-2 to cytotoxic J-series prostaglandin analogs. 
 







Arvanil is a structural hybrid of the endocannabinoid, AEA, and the potent transient 
receptor potential cation channel subfamily V member 1 (TRPV-1) agonist, capsaicin. Arvanil 
demonstrates affinity for the CB1 receptor comparable to AEA, activates TRPV-1 more potently 
than capsaicin, inhibits the anandamide membrane transporter (AMT), and inhibits FAAH’s ability 
to hydrolyze endocannabinoids (Melck et al. 1999b, Glaser et al. 2003). Sancho et al. demonstrated 
arvanil-induced apoptosis in the Jurkat cell line via a FADD/caspase-8 dependent pathway 
(Sancho et al. 2009). Similar to AEA, arvanil can be metabolized by COX-2, but the rate of 
metabolism is 5.6% that of AA (Prusakiewicz et al. 2007).  Interestingly, COX-2 metabolites of 
arvanil, including J-series metabolites, have not been reported.  
 
1.6: Arachidonoyl Glycine (NAGly) 
 NAGly is a carboxylic analog of the endocannabinoid AEA.  It was identified as an 
endogenous conjugate of arachidonic acid and glycine that is produced in response to 
inflammatory pain (Huang et al. 2001). NAGly also inhibits the hydrolytic activity of FAAH on 
AEA, effectively serving as an endogenous regulator of AEA concentrations (Burstein et al. 2002).  
NAGly was the first charged species identified to be metabolized selectively by COX-2 to PGH2-
Gly and is metabolized at 40% the rate of AA (Prusakiewicz et al. 2002, Prusakiewicz et al. 2007).  
However, it is unclear if J-series metabolites of NAGly are produced by the COX-2 metabolic 






1.7: COX-2 and FAAH Expression Levels Regulate the Cytotoxicity of AEA  
NMSC, colorectal cancer, and other epithelial cancers overexpress COX-2, creating a 
potential target for chemotherapeutics (Buckman et al., 1998). As stated earlier, AEA’s 
cytotoxicity relies on the overexpression of COX-2 which metabolizes AEA to 15dPMJ2, the 
primary cancer-killing metabolite (Soliman et al. 2016a, Ladin et al. 2017).  If the expression of 
COX-2 is low in cancer cells, the metabolism of AEA to J-series prostamides will be reduced.    
FAAH’s activity is also crucial because high levels of FAAH will lower the concentration of AEA 
thereby reducing the production of J-series prostamides.  To identify an appropriate model for our 
studies, we screened a series of NMSC and colon cancer cell lines.  We found that both murine 
JWF2 NMSC cells and human colon cancer HCA-7 cells overexpressed COX-2 and expressed 
low levels of FAAH (Soliman 2014).  Hence, JWF2 and HCA-7 cells were used for the studies 
described in this dissertation.  
 
1.8: Synthesis of AEA 
 AEA can be chemically synthesized from its base components, arachidonic acid and 
ethanolamine via an amide coupling reaction in a “one-pot” synthesis (Scheme 1.5).  This synthesis 
is optimized to produce derivatives in a simple yet efficient manner.  The uronium amide coupling 
reagent, N,N,N',N'-tetramethyuronium tetrafluoroborate (TBTU), is most commonly used in 
peptide syntheses, but in this instance works efficiently to couple AA and ethanolamine.   The 
solvent, acetonitrile, is a crucial choice as it is polar enough to bring the ethanolamine into solution, 
but nonpolar enough to dissolve the arachidonic acid which contains a significantly non-polar 
chain.  Once AA is activated via TBTU, the ethanolamine is added in excess to assure all AA, 
which is the more costly reagent, is converted to AEA to maximize efficiency and for ease of 
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purification.  This synthesis typically yields greater than 95% AEA.  This amide coupling reaction 
is a general synthesis which can be used to make any number of AEA derivatives with the 
expectation of the same purity and yield 
 
 






AEA is an endocannabinoid that demonstrates cytotoxicity in cancer cell lines that 
overexpress the enzyme, COX-2.  We have previously demonstrated AEA’s anti-cancer activity is 
due to its metabolism by COX-2, followed by PGDS, and subsequent dehydrations to 15d-PMJ2 
(Kuc et al. 2012, Soliman et al. 2016a, Ladin et al. 2017).  This metabolic pathway and resulting 
cytotoxicity can be disrupted by the hydrolase activity of FAAH, which degrades AEA to AA and 
ethanolamine, thereby reducing its anti-cancer activity.  This system of metabolic and cytotoxic 
pathways provides an opportunity to improve the anti-cancer activity of AEA, and more 
specifically, the cytotoxicity of the J-series prostamide, 15d-PMJ2.   
 Since AEA is a prodrug requiring metabolic processing for production of the 
pharmacologically active drug, and there is a competing pathway for degradation of the prodrug, 
the complexity of the system makes thoroughly isolating one area difficult. We hypothesized there 
were four parts of this system where we could improve AEA’s killing activity in cancer cells that 
have both COX-2 and FAAH activity.  These four areas of improvement are 1) inherent 
cytotoxicity of the final J-series prostamide metabolites, 2) rate of COX-2 metabolism, 3) rate of 
and bias for PGDS metabolism, and 4) resistance to degradation by FAAH (Scheme 1.6). The 
approach outlined below, which employs 10 AEA derivatives, allows us to make informed 
judgments as to which of the four areas leads to the greatest enhancement of anti-cancer activity 
and what structural features are required to achieve this.
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Scheme 1.6: Contributing Factors in AEA’s Cytotoxic Pathway 
 
                                   
1. Cytotoxicity of 15d-PMJ2   
2. COX-2 metabolism  
3. PGDS metabolism 





Specific Aim 1: Synthesize and screen initial AEA derivatives for cytotoxic activity in JWF2 
and HCA-7 cell lines and select candidates with equal or greater activity than AEA.  
It was demonstrated in previous studies that linking ethanolamine to AA via an amide bond 
increases cytotoxicity, thus only modifications at the ethanolamine end of AEA were explored 
(Kuc et al. 2012). Modifications at this location were also predicted to have minimal or no impact 
on its ability to be metabolized by COX-2 into prostaglandin analogs, specifically cytotoxic J-
series prostamides, because metabolism takes place on the long carbon chain backbone of AEA 
(Scheme 1.1).  AEA derivatives were synthesized from AA and an appropriate amine to yield the 
desired modification on the ethanolamide arm when coupled using the methodology employed for 
the synthesis of AEA. 
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 A first generation of seven AEA analogs was designed to create a broad overview of 
modifications that induce positive or negative effects on anti-cancer activity.  The modifications 
were made based on aspects of AEA’s metabolic pathways and their role in cytotoxicity.  Six of 
the seven AEA analogs, R1-methanandamide, arvanil, NAGly, arachidonoyl diethanolamine 
(ADA), arachidonoyl serinol (AS), and arachidonoyl propanolamine (A-Pro) were included in the 
first generation because of their demonstrated or hypothesized resistance to FAAH degradation.  
All seven of the AEA analogs were included in the first generation because of their demonstrated 
or hypothesized metabolism by COX-2 and PGDS.  The cytotoxicity of the first generation AEA 
analogs was determined in COX-2 overexpressing cancer cells and was classified as hits if they 
demonstrated equal or better cytotoxicity than AEA when applied to cancer cells.  A second 
generation of AEA analogs was then created for the most potent first generation molecule(s) to 
further refine our understanding of the structural modifications associated with cytotoxicity. 
 
Specific Aim 2: Determine the role of the endocannabinoid system on the cytotoxic AEA 
derivatives identified in the SAR studies. 
 The AEA derivatives from the SAR study that produce cytotoxicity that is equal or greater 
than AEA will be biochemically characterized.  The endocannabinoid system is composed of 
cannabinoid receptors as well as COX-2 and FAAH, which regulate the activity of AEA.  
Therefore, we examined the role of the most important receptors and enzymes of the 
endocannabinoid system in the anti-cancer activity of the AEA derivatives.  These studies were 
also utilized to determine the importance of the added functional groups and their effect on the 
cytotoxicity of their J-series metabolite
 
 
CHAPTER TWO: MATERIALS AND METHODS 
2.1: Synthesis Reagents  
Arachidonic acid was purchased from NuChek Prep (Elysian, MN). AEA, R1-
methanandamide, AM404, arachidonoyl glycine, arvanil, arachidonoyl 2’-chloroethylamide, 
arachidonoyl serinol, AM251, and AMG9810 were purchased from Cayman Chemical Company 
(Ann Arbor, MI). 4-hydroxybenzylamine, 3,4-dimethoxybenzylamine, propanolamine, and 
diethanolamine were purchased from Sigma-Aldrich (St. Louis, MO). Acetonitrile, O-
(benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium tetrafluoroborate (TBTU), N,N-
diisopropylethylamine (DIEA), and 1-hydroxybenotriazole (HOBt) were purchased from Sigma-
Aldrich (St. Louis, MO).  
 
2.2: Synthesis, Purification, and Characterization of AEA and All AEA Derivatives 
 This is the general synthetic procedure for producing AEA and the related AEA 
derivatives. 20 mg of AA was first added to 20 mL of acetonitrile followed by 1:1 molar 
equivalents of DIEA and TBTU.  This solution was allowed to mix for 5 minutes to ensure the AA 
was primed for reaction.  Four molar equivalents of ethanolamine or appropriate amine reagent (to 
produce the target derivative) was then mixed into the solution and stirred for 1 hour at room 
temperature.  Once stirred and reacted sufficiently, the mixture was added to a separation funnel 
followed by 20 mL of distilled water and 20mL of diethyl ether and the funnel was swirled gently 
for 30 seconds.  The water was drained from the separation funnel and the previous step was 
repeated two more times to remove the polar reaction products and all impurities.  The ether layer 
containing the water-insoluble product was dried on a Rotovap at 40oC.  All synthesized and 




Figure 2.1: NMR Characterization of Synthesized AEA 
 
2.3: Cell Culture  
 The JWF2 murine squamous carcinoma cell line (MD Anderson Cancer Center, Smithville, 
TX) was cultured in Eagle’s minimal essential media (US Biological) containing 5% heat-
inactivated fetal bovine serum (FBS), 100 mg/ml penicillin, 100 mg/ml streptomycin, nonessential 
amino acids, and glutamine. HCA-7 human colorectal cancer cell line (Sigma-Aldrich, St. Louis, 
MO) were cultured in Dulbecco’s minimal essential media (Invitrogen) containing 10% heat-
inactivated FBS, 100 mg/mL penicillin, 100 mg/mL streptomycin, and 1mM sodium pyruvate.   
 
2.4: MTS Cell Viability Assays 
 Cells were plated in 96-well plates and cultured for 48 hours until 80% confluency was 
achieved.  Serum-free media containing varying concentrations of appropriate molecules were 
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added to the cells for 24 hours.  A 20 µL aliquot of MTS reagent (Promega, Madison, WI) was 
added to each well as described by manufacturer and the absorbance was measured at 495 nm. 
 
2.5: ELISA Assay 
 JWF2 and HCA-7 cells were treated with vehicle, AEA, NAGly, and arvanil for 8 hours.  
Media was obtained after 8 hours and D-series prostaglandins, prostamides, and prostaglandin 
analogs were measured with ELISA kits as described by the manufacturer’s instructions. 
 
2.6: Caspase-3/7 Activity Assay 
 HCA-7 cells were plated in 96-well plates and cultured for 48 hours until 80% confluency 
was achieved. Serum-free media containing 20 µM of vehicle, AEA, NAGly, and arvanil alone, 
and each agent was also pre-treated and co-treated with SeCl4.  A 100 µL aliquot of Caspase-Glo 
3/7 reagent (Promega, Madison, WI) was added to each well as described by manufacturer and 
luminescence was measure using a Tecan luminometer. 
 
2.7: Liquid Chromatography-Mass Spectrometry (LC-MS) 
 HCA-7 cells were treated with arvanil for 8 hours and cell media was removed.  Lipids 
were extracted from acidified media using solid phase extraction (SPE).  1 mL Strata X reverse 
phase cartridges were equilibrated then applied with 1 mL of acidified media.  The sample was 
washed with ultrapure deionized water followed by 15% acetonitrile.  Lipids were eluted with 
100% hexane followed by 100% acetonitrile and then allowed to dry overnight.  Samples were 
then reconstituted in 100 µL of 100% acetonitrile with 0.1% formic acid.  LC-MS was conducted 
on a SCIEX Eskigent/5600+ Triple TOF mass spectrometer in negative ionization mode with an 
18 
 
electrospray ionization source.  LC was equipped with a Luna NH2 normal phase column (150 mm 
x 0.3 mm, 3 µm particle size) and a gradient with A: Water with 0.1% formic acid and B: 
Acetonitrile with 0.1% formic acid.   
 
2.8: Statistical Analysis 
 Presented data is shown as mean ± standard error of mean.  One-way analysis of variance 




CHAPTER THREE: SYNTHESIS AND CYTOTOXICITY OF AEA 
DERIVATIVES 
 
3.1: Design of Experimental Approach  
AA, the non-ethanolamine conjugated molecule, and AEA are metabolized by COX-2 to 
series of prostaglandins and prostamides, respectively. Previously, we demonstrated that AEA was 
more cytotoxic than AA, suggesting that the ethanolamine moiety enhanced its activity (Kuc et. al 
2012).  Understanding the importance of the ethanolamine end, we hypothesized that this portion 
of the molecule could be modified to create a more cytotoxic chemotherapeutic.  After we 
determined that AEA’s anti-cancer activity was due to its metabolism by COX-2 to 15d-PMJ2, we 
also hypothesized that modifications of the ethanolamide region of the molecule will increase anti-
cancer activity without interfering with COX-2 metabolism (Soliman et al. 2016a).  Our data 
showed that the pharmacophore of 15d-PMJ2 was the double bond located in the cyclopentonone 
ring (Ladin et al. 2017). As such, modifying the ethanolamide region of AEA should not interfere 
with the COX-2 metabolism of the AEA analogs or the pharmacophore responsible for the anti-
cancer activity of 15d-PMJ2. 
The intent of this investigation is to determine how structural modification of the 
ethanolamine moiety of AEA affects anti-cancer activity with the aim of creating improved 
therapeutics.  Using a series of AEA derivatives designed to alter the action of key enzymes in the 
metabolism of the prodrug, including COX-2, PGDS, and FAAH, allows us to postulate whether 
the final J-series prostamide analog metabolite will be cytotoxic.
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The target of 15d-PMJ2 which induces apoptotic cancer cell death is currently unknown, 
however we hypothesize that the physiochemical features of the ethanolamide group enhances 
recognition or binding to this target compared to 15d-PGJ2 or that the ethanolamide group 
stabilizes the molecule.  Using the ethanolamide as a template, 10 AEA derivatives were designed 
and are shown in Table 3.1.  These molecules will allow us to explore the influence of 1) branching 
along the chain, 2) linkage via a tertiary amide, 3) presence of an aromatic ring, and 4) polarity of 
the terminus on the derivative’s cytotoxicity. 
With the goal of this study to improve the chemotherapeutic AEA, the activity 
demonstrated by AEA was utilized as a baseline for minimum anti-cancer activity for this SAR 
study.  AEA contains a 20 carbon-chain backbone with a secondary amide connection to an 
ethanolamine end.  The 20 carbon-chain dominates the overall polarity of the molecule leading to 
a lipohilic molecule, but the ethanolamine slightly contributes to the overall polarity of AEA which 
is slightly different than the polarity of AA and its carboxylic acid end.  As discussed earlier, the 
ethanolamine greatly increases the anti-cancer activity of the molecule.  When considering what 
chemical changes are made to the molecule that could increase its activity, the slight change in 
polarity may contribute to differences in the ability to bind to the catalytic pocket of COX-2 and 
the subsequent metabolism.  With this in mind, modifications to AEA investigated in this SAR 
should explore the hypothesis that minor changes in polarity of the molecule could enhance or 
disrupt the metabolism and cytotoxic activity of AEA analogs. 
 The difference in molecular size or length of AA and AEA are not huge, but are noticeable 
when considering the difference in anti-cancer activity.  When compared to AA, the size of AEA 
is slightly larger. AEA still contains the 20 carbon-chain backbone of AA, but extends the molecule 
by two more carbons and a hydroxyl group.  Just as the polarity change of the molecule is slight 
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but could be vitally important to the activity of the molecule, this size and length difference is 
minor but could be important to the anti-cancer activity of AEA.  To investigate these changes, 
modifications made in some molecules in the SAR will be made to determine if molecule size in 
the ethanolamide region or distance between the amide bond and terminal hydroxyl end in AEA 
are crucial to the improvement or disruption of anti-cancer activity.  These changes in anti-cancer 
activity could be related to increased or decreased target recognition, rate of COX-2 metabolism, 
or inhibition of FAAH’s hydrolase activity. 
 A key aspect of AEA’s anti-cancer activity is its metabolism by COX-2.  Within the SAR 
study, modifications are limited to the ethanolamine region of AEA due to the hypothesis that 
altering the 20-carbon chain alters COX-2 metabolism of the molecule.  Using this strategy, we 
can identify the importance of each modification to its chemotherapeutic activity without 
disrupting metabolism by COX-2, demonstrated vital to the anti-cancer activity of AEA.  Identified 
in Scheme 1.1, the important region of AA responsible for COX-2 metabolism is between C-8 and 
C-15.  With this knowledge, the assumption was made that any changes to this region of the 
molecule or even any part of the molecule close to this region would hinder COX-2 metabolism 











3.1.1: Expression of COX-2 and FAAH in JWF2 NMSC and HCA-7 Cell Lines 
 We have shown that AEA is cytotoxic in cancer cell lines that overexpress COX-2 (Van 
Dross 2009, Soliman et al. 2016a).  Also, we understand FAAH’s hydrolase activity on AEA is 
detrimental to its cytotoxicity (Kuc et al. 2012).  Therefore, previously we screened epithelial 
cancer cell lines, including NMSC and colorectal cancer cell lines, to observe COX-2 and FAAH 
expression.  We identified two cell lines, JWF2 NMSC and HCA-7 colorectal cancer, that 
overexpress COX-2 and have little expression of FAAH.  Utilizing these two cell lines, we 
established a model for our SAR study and any further studies. 
 
Figure 3.1: Expression of COX-2 and FAAH in JWF2 NMSC and HCA-7 Cell Lines 
Courtesy of Eman Soliman (Soliman, 2014).  Western blot analysis was conducted to compare COX-2 and FAAH 
expression in HCA-7 colorectal cancer cells and JWF2 tumorigenic keratinocytes. JWF2 and HCA-7 cells 





3.2: Cytotoxicity of AEA in JWF2 and HCA-7 
To establish a benchmark of anti-cancer activity for comparison with all AEA analogs, 
JWF2 NMSC cells and HCA-7 colorectal cancer cells were treated with AEA at three different 
concentrations, 10 µM, 20 µM, and 40 µM.  The activity demonstrated by AEA was utilized as a 
baseline for minimum anti-cancer activity for an AEA analog to be considered a “hit” that will be 
studied in greater detail.  In both JWF2 and HCA-7 cell lines, AEA caused a statistically significant 
reduction in cell viability at 20 µM, but it did not significantly reduce cell viability at 10 µM.  
Results at 40 µM were not used for comparison in the SAR because 20 µM supplied the lowest 
concentration of AEA with maximum reduction in cell viability.   This creates a concentration 
dependent comparison in both cell lines for all AEA analogs tested for “hits”.  Using the 
established cytotoxicity data for AEA, each AEA analog’s % cell viability reduction at 
concentrations of 10 µM and 20 µM can be compared to AEA.  For an AEA analog to be 
considered a “hit”, we set the following % cell viability thresholds: 
JWF2 
• 80% cell viability (20% reduction in cell viability) at 10 µM, or 
• 25% cell viability (75% reduction in cell viability) at 20 µM 
HCA-7 
• Less than 100% cell viability (Any % reduction in cell viability) at 10 µM, or 





Figure 3.2: Cytotoxicity of AEA in JWF2 and HCA-7  
JWF2 tumorigenic keratinocytes and HCA-7 colorectal cancer cells were treated with 10 µM, 20 µM, and 40 µM 
concentrations of AEA. Cell viability was evaluated by MTS assay according to manufacturer’s instructions. Data 
represents mean ± SEM of three independent experiments and are expressed as percent viability compared to untreated 
cells. Data were analyzed using one-way ANOVA followed by Tukey’s analysis (P < 0.05 = *) when compared to 








3.3: Cytotoxicity of R1-Methanandamide in JWF2 and HCA-7 
R1-methanandamide’s structure is identical to AEA except for the addition of a methyl 
group on the alpha carbon of the ethanolamide moiety. The methyl group addition makes the 
molecule a poor substrate for FAAH, in turn making R1-methanandamide a more metabolically 
stable molecule than AEA (Abadji et al. 1994).  As shown in Scheme 1.2, FAAH is responsible 
for degrading AEA to AA and ethanolamine which inhibits its cytotoxicity (Kuc et al. 2012). With 
its resistance to FAAH degradation, we expected to observe an increase in cytotoxicity due to an 
increase in J-series prostamide production. 
When JWF2 NMSC cells were treated with R1-methanandamide we observed a 40.5% 
reduction in cell viability at a concentration of 10 μM and a 78.4% reduction in cell viability at 20 
μM. When HCA-7 colorectal cancer cells were treated with R1-methanandamide in vitro we did 
not observe a reduction in cell viability at 20 μM.  These data suggest a modification to prevent 
degradation by FAAH does not correlate with an increase in anti-cancer activity when compared 
to AEA.  
Our hypothesis stated that modifying the molecule with a methyl group on the alpha carbon 
of ethanolamide would resist degradation by FAAH leading to an increase in cytotoxicity.  
Although R1-methanandamide meets the % reduction in cell viability in JWF2 cells, it does not in 





Figure 3.3: Cytotoxicity of R1-Methanandamide in JWF2 and HCA-7 
JWF2 tumorigenic keratinocytes and HCA-7 colorectal cancer cells were treated with 10 µM, 20 µM, and 40 µM 
concentrations of M-AEA. Cell viability was evaluated by MTS assay according to manufacturer’s instructions. Data 
represents mean ± SEM of three independent experiments and are expressed as percent viability compared to untreated 
cells. Data were analyzed using one-way ANOVA followed by Tukey’s analysis (P < 0.05 = *) when compared to 








3.4: Cytotoxicity of Arachidonoyl Glycine (NAGly) in JWF2 and HCA-7 
NAGly is an endocannabinoid and a carboxylic metabolite of AEA (Burstein et al. 2002, 
Bradshaw et al. 2009).  The molecular structure differs from AEA by substituting a carboxylic 
acid moiety for the terminal alcohol introducing a more polar molecule. The structure of NAGly 
is like AA as it contains a terminal carboxylate moiety which we predict will allow for the same 
binding events to a target that takes place with AA.  NAGly is reported to be a selective substrate 
for COX-2 over COX-1 and has a higher rate of metabolism by COX-2 compared to AEA and 
other known arachidonoyl derivatives (Prusakiewicz et al. 2002, Prusakiewicz et al. 2007, Kozak 
et al. 2002). 
When JWF2 NMSC cells were treated with NAGly we observed an 88.4% reduction in 
cell viability at a concentration of 20 μM. When HCA-7 colorectal cancer cells were treated with 
NAGly we did not observe a reduction in cell viability at 20 μM.  NAGly demonstrates a decrease 
in anti-cancer activity in HCA-7 cells, but we examined it in further studies based on its 
cytotoxicity in JWF cells. 
NAGly has a COX-2 metabolic rate 40% that of AA, which as stated earlier is high 
compared to other arachidonoyl derivatives. (Prusakiewicz, et al. 2007) Considering our model 
system is dependent on COX-2 metabolism, our hypothesis was that an AEA analog containing a 
high rate of COX-2 metabolism would lead to a large concentration of prostamides.  With an 
increase in prostamides, there should be an increase in cancer-killing J-series prostamides which 
would lead to increased anti-cancer activity.  In these results, we do not see that increased anti-
cancer activity, but we do still see anti-cancer activity that meets our hit thresholds in JWF2.  
Considering all of this, we wanted to take NAGly to further studies and explore its production of 
D- and J-series prostaglandin analogs.  These studies can identify if rate of metabolism by COX-
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2 is important, if there is bias for other prostaglandin synthases other than PGDS, or if the 




Figure 3.4: Cytotoxicity of Arachidonoyl Glycine (NAGly) in JWF2 and HCA-7 
 JWF2 tumorigenic keratinocytes and HCA-7 colorectal cancer cells were treated with 10 µM, 20 µM, and 40 µM 
concentrations of NAGly. Cell viability was evaluated by MTS assay according to manufacturer’s instructions. Data 
represents mean ± SEM of three independent experiments and are expressed as percent viability compared to untreated 
cells. Data were analyzed using one-way ANOVA followed by Tukey’s analysis (P < 0.05 = *) when compared to 









3.5: Cytotoxicity of Arvanil in JWF2 and HCA-7 
Arvanil is a hybrid endocannabinoid/capsaicin molecule with affinity for the CB1 receptor 
and the TRPV1 receptor (Di Marzo et al. 2001). It is metabolized by COX-2 with a rate that is 
5.6% that of AA (Prusakiewicz et al. 2007). The molecular structure of arvanil contains the biggest 
difference in structure compared to AEA of any of the derivatives tested.  Our goal was to observe 
how adding steric bulk with the addition of a benzene ring between the amide bond and the 
terminal moieties, would affect COX-2 metabolism and in turn, anti-cancer activity.  The structure 
still contains a terminal hydroxyl group, but also contains a terminal methyl ether which is a moiety 
that has not been explored in previous studies. The methoxy group not only adds more steric bulk 
to the ring, but also increases the electron density.  Another critical property of arvanil is that it is 
resistant to degradation by FAAH. 
When JWF2 NMSC cells were treated with arvanil, an 89.5% reduction in cell viability at 
10 μM and an 86% reduction in cell viability at 20 μM occurred.  When HCA-7 colon cancer cells 
were treated with arvanil, a 46.3% reduction in cell viability at 10 μM and an 89.4% reduction in 
cell viability at 20 μM was observed.   
The cytotoxicity results from arvanil suggest that steric bulk added to the ethanolamide end 
via a benzene ring can be tolerated when considering metabolism by COX-2 and PGDS.  It is 
reported that arvanil’s rate of metabolism by COX-2 is lower than AEA, but that lower rate of 
metabolism does not necessarily contribute to a decrease in anti-cancer activity and in this case the 
anti-cancer activity was increased.  This leads to the hypothesis that the concentration of J-series 
prostamides is not as important as the activity of those J-series prostamides. To investigate this 
hypothesis further, more studies were completed to identify novel D- and J-series prostaglandin 
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analogs that were derived from arvanil with increased cytotoxicity when compared to 15d-PMJ2.  




Figure 3.5: Cytotoxicity of Arvanil in JWF2 and HCA-7 
JWF2 tumorigenic keratinocytes and HCA-7 colorectal cancer cells were treated with 10 µM, 20 µM, and 40 µM 
concentrations of arvanil. Cell viability was evaluated by MTS assay according to manufacturer’s instructions. Data 
represents mean ± SEM of three independent experiments and are expressed as percent viability compared to untreated 
cells. Data were analyzed using one-way ANOVA followed by Tukey’s analysis (P < 0.05 = *) when compared to 







3.6: Cytotoxicity of Arachidonoyl Diethanolamine (ADA) in JWF2 and HCA-7 
 Arachidonoyl diethanolamine (ADA) retains similar structure to AEA, but with the 
addition of a second ethanolamine end.  The tertiary amide in ADA removes the hydrogen from 
the amide bond, thus affecting any binding or signaling event that requires a hydrogen bond 
associated with a secondary amide.  If binding of the hydroxyl group to its target regulates the 
cytotoxicity of AEA, then adding a second terminal hydroxyl group should increase the probability 
of this binding event in turn increasing anti-cancer activity. 
When JWF2 NMSC cells were treated with ADA we observe a 22.5% reduction in cell 
viability at a concentration of 10 μM and a 7.2% reduction in cell viability at a concentration of 
20 μM. When HCA-7 colorectal cancer cells were treated with ADA we observe no reduction in 
cell viability at 10 μM or 20 μM.   
With these results, our hypothesis that adding a second branch from the amide bond with 
a terminal hydroxyl did not come to fruition.  Adding a second terminal hydroxyl did not increase 
anti-cancer activity, but instead decreased the anti-cancer activity of AEA.  With these results, 




Figure 3.6: Cytotoxicity of Arachidonoyl Diethanolamine (ADA) in JWF2 and HCA-7 
JWF2 tumorigenic keratinocytes and HCA-7 colorectal cancer cells were treated with 10 µM, 20 µM, and 40 µM 
concentrations of ADA. Cell viability was evaluated by MTS assay according to manufacturer’s instructions. Data 
represents mean ± SEM of three independent experiments and are expressed as percent viability compared to untreated 
cells. Data were analyzed using one-way ANOVA followed by Tukey’s analysis (P < 0.05 = *) when compared to 




3.7: Cytotoxicity of Arachidonoyl Serinol (AS) in JWF2 and HCA-7 
 On the other hand, the decreased cytotoxicity of ADA may be due to the change from a 
secondary amide to a tertiary amide.  This amide bond change could have decreased the molecule’s 
ability to bind to its target.  To test this theory, the next molecule investigated was arachidonoyl 
serinol (AS) which contains the same second terminal hydroxyl moiety but retains the secondary 
amide of AEA.  AS is structurally similar to AEA and ADA in terms of polarity and size of the 
molecule.  The modification, a second terminal hydroxyl moiety, which were investigated with 
ADA is the same being explored by AS.  The difference between AS and ADA is, with AS, the 
secondary amide present in AEA is retained instead of replaced by a tertiary amide. 
When JWF2 NMSC cells were treated with AS we observe no reduction in cell viability at 
a concentration of 10 μM and a 14.3% reduction in cell viability at a concentration of 20 μM. 
When HCA-7 colorectal cancer cells were treated with AS we observe no reduction in cell viability 
at 10 μM or 20 μM.   
These results confirm our hypothesis established by ADA that adding a branch with a 
second hydroxyl reduces or abrogates the anti-cancer activity of the molecule.  By removing the 
tertiary amide of ADA and replacing it with the secondary amide of AEA, but keeping the 
branched ethanolamine end with two hydroxyl moieties, we tested the hypothesis that the tertiary 
amide is responsible for removal of anti-cancer activity.  AS maintained the same decrease in anti-
cancer activity, so it was determined the tertiary amide did not play the major role in the reduction 
of anti-cancer activity.  As such, we do not consider AS a hit and further study of this molecule 
will not be conducted.   
This leads to the assumption that either of these structural modifications, a branched 
ethanolamine end with two terminal hydroxyls or a tertiary amide, lead to a removal of anti-cancer 
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activity.  This could be through removal of binding ability at the target or through obstruction of 




Figure 3.7: Cytotoxicity of Arachidonoyl Serinol (AS) in JWF2 and HCA-7 
JWF2 tumorigenic keratinocytes and HCA-7 colorectal cancer cells were treated with 10 µM, 20 µM, and 40 µM 
concentrations of AS. Cell viability was evaluated by MTS assay according to manufacturer’s instructions. Data 
represents mean ± SEM of three independent experiments and are expressed as percent viability compared to untreated 
cells. Data were analyzed using one-way ANOVA followed by Tukey’s analysis (P < 0.05 = *) when compared to 








3.8: Cytotoxicity of Arachidonoyl Propanolamine (A-Pro) in JWF2 and HCA-7 
AEA contains a two-carbon chain separating the alcohol from the amide bond in the 
ethanolamine arm.  With the molecule arachidonoyl propanolamine (A-Pro), the theory that a two-
carbon chain is the perfect number and length was put to the test.  AP contains a three-carbon chain 
and allows us to investigate whether an odd number carbon chain and a slightly longer chain affects 
anti-cancer activity. The molecular structure is identical to AEA in every other way, as A-Pro 
retained the secondary amide and terminal hydroxyl group. 
When JWF2 NMSC cells were treated with A-Pro we observed an 11.4% reduction in cell 
viability at a concentration of 10 μM and a 37.8% reduction in cell viability at a concentration of 
20 μM. When HCA-7 colorectal cancer cells were treated with A-Pro we observe no reduction in 
cell viability at 10 μM or 20 μM. 
When compared to AEA, we see a reduction in cytotoxicity with A-Pro.  These data 
demonstrate that the anti-cancer activity is very sensitive to the distance between the amide bond 
and the terminal hydroxyl moiety.  This modification to the structure should not interfere with 
COX-2 or PGDS metabolism, so it appears the effect is directly related to the inherent cytotoxicity 
of the 15d-PMJ2 analog.  Extending the length between the amide bond and hydroxyl moiety 
causing reduction in anti-cancer activity contrasts with arvanil.  The distance between these two 
groups in arvanil is five carbons whereas the distance in A-Pro is only three carbons.  This suggests 
that there is not a single fixed length we must maintain, but there are multiple distances that 
produce anti-cancer activity, and others that remove anti-cancer activity.  With these results, A-





Figure 3.8: Cytotoxicity of Arachidonoyl Propanolamine in JWF2 and HCA-7 
JWF2 tumorigenic keratinocytes and HCA-7 colorectal cancer cells were treated with 10 µM, 20 µM, and 40 µM 
concentrations of A-Pro. Cell viability was evaluated by MTS assay according to manufacturer’s instructions. Data 
represents mean ± SEM of three independent experiments and are expressed as percent viability compared to untreated 
cells. Data were analyzed using one-way ANOVA followed by Tukey’s analysis (P < 0.05 = *) when compared to 







3.9: Cytotoxicity of Arachidonoyl 2'-Ethylchloroamide (AC) in JWF2 and HCA-7 
In these cytotoxicity experiments we wanted to investigate the importance of the terminal 
alcohol end of the ethanolamine of AEA for maintaining cytotoxicity.  In arachidonoyl 2'-
chloroethylamide (AC) the hydroxyl group of AEA was replaced with a chlorine. The approach 
here was to observe whether the terminal alcohol, and its ability to serve as a hydrogen bond donor, 
was vital to the cytotoxicity of AEA or if any polar atom or moiety at the end of the ethanolamide 
arm still elicits anti-cancer activity.   
When JWF2 NMSC cells were treated with AC we observed a 17.5% reduction in cell 
viability at a concentration of 10 μM and a 57.5% reduction in cell viability at a concentration of 
20 μM. When HCA-7 colorectal cancer cells were treated with AC we observe no reduction in cell 
viability at 10 μM or 20 μM.   
Hence, AC does have anti-cancer activity in JWF2 cells, but it is less cytotoxic than AEA. 
This leads us to conclude that polar groups are not interchangeable at the terminal end of AEA.  
We anticipate that this modification will not affect the metabolism of AC by COX-2 or PGDS.  
One of the goals of this modification was to identify if hydrogen bond accepting or donating is 
crucial for the anti-cancer activity of AEA. Examination of the results for NAGly and AC reveals 
that having a negatively charged group, i.e. a carboxylate, or hydrogen bonding donor is important 
for preserving cytotoxicity similar to that of AEA.  AC is not considered a hit and was not carried 





Figure 3.9: Cytotoxicity of Arachidonoyl 2'-Ethylchloroamide in JWF2 and HCA-7 
JWF2 tumorigenic keratinocytes and HCA-7 colorectal cancer cells were treated with 10 µM, 20 µM, and 40 µM 
concentrations of AC. Cell viability was evaluated by MTS assay according to manufacturer’s instructions. Data 
represents mean ± SEM of three independent experiments and are expressed as percent viability compared to untreated 
cells. Data were analyzed using one-way ANOVA followed by Tukey’s analysis (P < 0.05 = *) when compared to 








3.10: Second Generation SAR: Arvanil Analogs 
Results from the first generation SAR produced three hits: R1-methanandamide, NAGly, 
and arvanil.  Of these three hits, arvanil demonstrated the greatest cytotoxicity.  Therefore, three 
derivatives of arvanil, AM404, arvanil D1, and arvanil D2, were designed and synthesized or 
purchased.  When creating these arvanil analogs, we focused on the substituent pattern of the 
benzene ring (arvanil D1 and arvanil D2), and the length of the carbon chain separating the benzene 
ring from the amide bond (AM404) where a carbon was removed between the amide bond and the 
benzene ring. Moreover, because each of the three molecules are analogs of arvanil, we anticipate 
that their metabolism by COX-2 and PGDS metabolism will not be compromised.  Hence our 
goals were to: 1) identify the arvanil derivative with the greatest cytotoxicity and compare its 
cytotoxicity to arvanil, and 2) examine whether arvanil or the arvanil derivatives are metabolized 
by COX-2 and PGDS to J-series prostaglandins.  However, we only chose one, arvanil or arvanil 




3.10.1: Cytotoxicity of AM404 in JWF2 and HCA-7 
AM404 is a metabolite of acetaminophen (paracetamol). Acetaminophen undergoes a 
deacetylation to p-aminophenol in the central nervous system.  P-aminophenol is conjugated with 
arachidonic acid via FAAH to produce AM404, a molecule reported to be responsible for the 
analgesic action of acetaminophen (Hogestatt et al. 2005, Bisogno et al. 2002, Mallet et al. 2008, 
Muramatsu et al. 2016).  AM404 also inhibits proliferation in C6 glioma cells, an event that occurs 
due to blockade of AEA uptake (De Lago et al. 2006). This molecule maintains the steric bulk of 
arvanil via the benzene ring contained between the amide bond and the terminal alcohol, but the 
chain linking the amide bond to the benzene ring is one carbon shorter.   
When JWF2 NMSC cells were treated with AM404 we observe a 20% reduction in cell 
viability at a concentration of 10 μM and a 68% reduction in cell viability at a concentration of 20 
μM. When HCA-7 colorectal cancer cells were treated with AM404 we observe a 16.7% reduction 
in cell viability at 20 μM.   
Based on these results, AM404 contains some anti-cancer activity, but does not meet the 
cell viability threshold needed to be considered a hit.  In contrast to the rest of our AEA analogs, 
the interest in AM404 came from reported ability to inhibit COX-2 metabolism (Hogestatt et al. 
2005).  It is an interesting modification because its structure is similar to arvanil and arvanil D1, 
although the removal of one carbon in the chain length between the amide bond and hydroxyl 
group inhibits COX-2 metabolism.  When compared to the rate of metabolism by arvanil discussed 
earlier, this slight structure change is crucial for anti-cancer activity when comparing arvanil and 
AM404.  These results suggest that arvanil’s ability to be metabolized by COX-2 (AM404 is not 
metabolized by COX-2) is responsible for an increase in cytotoxicity of the molecule.  This 





Figure 3.10: Cytotoxicity of AM404 in JWF2 and HCA-7 
JWF2 tumorigenic keratinocytes and HCA-7 colorectal cancer cells were treated with 10 µM, 20 µM, and 40 µM 
concentrations of AM404. Cell viability was evaluated by MTS assay according to manufacturer’s instructions. Data 
represents mean ± SEM of three independent experiments and are expressed as percent viability compared to untreated 
cells. Data were analyzed using one-way ANOVA followed by Tukey’s analysis (P < 0.05 = *) when compared to 







3.10.2: Cytotoxicity of Arvanil D1 in JWF2 and HCA-7 
When creating arvanil D1, the methoxy substituent was completely removed from the 
benzene ring.  This was to explore the importance of the methoxy group for arvanil’s anti-cancer 
activity.  The terminal hydroxyl group of ethanolamide in 15d-PMJ2 is necessary for its anti-cancer 
activity. Therefore, arvanil D1 investigates whether a hydroxyl substituent leads to an increase in 
anti-cancer activity when compared to arvanil. Removal of the methoxy group not only decreases 
the steric bulk of the ring, but it also effects the charge density on the ring which, in turn, lowers 
the pKa of the hydroxyl group. 
When JWF2 NMSC cells were treated with arvanil D1 we observe an 80.3% reduction in 
cell viability at a concentration of 10 μM and a 97.8% reduction in cell viability at 20 μM. When 
HCA-7 colorectal cancer cells were treated with arvanil D1 we observe no reduction in cell 
viability at 10 μM and a 64.5% reduction in cell viability at 20 μM.   
Based on these results, it has been demonstrated that the methoxy substituent is not required 
for the anti-cancer activity of arvanil.  The cytotoxicity results of arvanil and arvanil D1 compared 
with the cytotoxicity results of AM404 suggests that the removal of the methoxy substituent does 
not interrupt the COX-2 metabolism of the molecule.  These results also continue to confirm the 
hypothesis that hydrogen bonding of a terminal hydroxyl moiety is required for the cytotoxicity of 
15d-PMJ2 analogs.  To continue testing this hypothesis we synthesized another arvanil analog, 





Figure 3.11: Cytotoxicity of Arvanil D1 in JWF2 and HCA-7 
JWF2 tumorigenic keratinocytes and HCA-7 colorectal cancer cells were treated with 10 µM, 20 µM, and 40 µM 
concentrations of arvanil D1. Cell viability was evaluated by MTS assay according to manufacturer’s instructions. 
Data represents mean ± SEM of three independent experiments and are expressed as percent viability compared to 
untreated cells. Data were analyzed using one-way ANOVA followed by Tukey’s analysis (P < 0.05 = *) when 





3.10.3: Cytotoxicity of Arvanil D2 in JWF2 and HCA-7 
When designing arvanil D2, instead of removing the methoxy substituent, like was done 
with arvanil D1, the hydroxyl substituent was replaced with a methoxy substituent.  This was to 
explore the importance of a hydroxyl group on the aromatic ring to the cytotoxicity of the 
molecule.  This modification changes the polarity of the molecule slightly and removes the 
hydrogen bond donating capability of the molecule. 
When JWF2 NMSC cells were treated with arvanil D2 we observed a 26.1% reduction in 
cell viability at a concentration of 10 μM and a 48.7% reduction in cell viability at 20 μM. When 
HCA-7 colorectal cancer cells were treated with arvanil D2 we did not observe a reduction in cell 
viability at 10 μM and an 18.4% reduction in cell viability at 20 μM.   
Based on these results, it was determined the hydroxyl substituent of arvanil is crucial to 
its anti-cancer activity.  The ongoing hypothesis of all AEA analogs is that hydroxyl moieties are 
required for maintaining a high level of cytotoxicity, whether for hydrogen bonding or other 
interactions with the binding site of 15d-PMJ2.  This hypothesis is further supported by the 
cytotoxicity results of the second generation arvanil analogs.  The reduction in cytotoxicity of 
arvanil D2, compared to arvanil D1 and arvanil, may be attributed to reduced COX-2 metabolism 
because of the increased steric bulk of a second methoxy substituent.  If reduced COX-2 
metabolism is the reason for the reduced cytotoxicity of arvanil D2, then substituents on the 





Figure 3.12: Cytotoxicity of Arvanil D2 in JWF2 and HCA-7 
JWF2 tumorigenic keratinocytes and HCA-7 colorectal cancer cells were treated with 10 µM, 20 µM, and 40 µM 
concentrations of arvanil D2. Cell viability was evaluated by MTS assay according to manufacturer’s instructions. 
Data represents mean ± SEM of three independent experiments and are expressed as percent viability compared to 
untreated cells. Data were analyzed using one-way ANOVA followed by Tukey’s analysis (P < 0.05 = *) when 







3.11: Summary and Conclusions of SAR Study 
In this study, we wanted to expand on our previous findings that demonstrate the 
chemotherapeutic activity of AEA.  Through an expansive structure-activity relationship study, 
the goal was to identify modifications that can be made to AEA to increase its overall anti-cancer 
activity (Table 3.2).  Each of the following parameters were taken into consideration when 
designing the analogs of AEA; (1) cytotoxicity of the prostamide analog, (2) its ability to be 
metabolized by COX-2, (3) its ability to be metabolized by PGDS, and (4) its resistance to FAAH 
degradation.  When designing AEA analogs, modifications were made to the ethanolamide portion 
of the structure to specifically identify characteristics that are important or can improve AEA’s 
anti-cancer activity. These modifications can be grouped into one or multiple of the following 
categories; branching along the carbon chain, alteration of the hydrogen-bonding ability at the 
chain terminus, and the addition of an aryl ring. Many of these modifications are known to affect 
rate of metabolism by one or more of the aforementioned enzymes.  In this SAR, the analogs were 
screened for their cytotoxicity and those with comparable cytotoxicity to AEA were selected for 
further screening to determine if the J-series prostaglandin analogs were produced and necessary 
for cytotoxicity.  With the knowledge of how certain modifications affect an analog’s metabolism 
combined with that analog’s cytotoxicity profile, we can better assess how a structural 
modification impacts the J-series prostamide analog’s cytotoxic potential. 
 The results of cytotoxicity studies with AEA in JWF2 NMSC cells and HCA-7 colorectal 
cancer cells gave us a minimum activity level to use as a benchmark for all of the AEA analogs 
investigated in this study.  The cell viability at concentrations of 10 μM and 20 μM in both cell 
lines was compared to AEA’s cell viability at the same concentrations to generate AEA analog 
hits.  The AEA analogs meeting the hit threshold for the first-generation SAR were R1-
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methanandamide, NAGly, and arvanil, and the only hit from the second-generation SAR was 
arvanil D1.  Of these AEA analogs, NAGly and arvanil were examined further to determine if 
these molecules are metabolized COX-2/PGDS to J-series prostaglandins.  R1-methanandamide, 
even though its cytotoxicity was within the hit threshold, was not carried on to further studies.  The 
methyl group modification of R1-methanandamide, responsible for resisting degradation by 
FAAH, was hypothesized to increase cytotoxicity compared to AEA.  Without seeing an increase 
in its cytotoxicity in JWF2 and a loss of cytotoxicity in HCA-7 at 20 μM, we deemed it to possess 
weak potential as an anti-cancer candidate.  Arvanil D1 was a part of the SAR second generation 
of arvanil analogs, which we stated were not going to be carried on to further studies, unless a 
statistically significant increase in cytotoxicity was demonstrated compared to arvanil.  This 
compound did not meet this threshold and thus was not studied further.  
 Degradation by FAAH is an important aspect in the cytotoxic potential of AEA, and it was 
previously demonstrated that blockade by a FAAH inhibitor enhanced cytotoxicity of AEA (Kuc 
et al. 2012).  First generation AEA analogs that are hypothesized or have demonstrated an inherent 
resistance to FAAH degradation were R1-methanandamide, NAGly, arvanil, AS, and ADA 
(Abadji et al. 1994, Burstein et al. 2002, Di Marzo et al. 1998).  These four AEA analogs 
demonstrated dramatically different anti-cancer activity compared to AEA at 10 μM and 20 μM, 
no cytotoxicity from AS and ADA, similar or decreased cytotoxicity depending on the cell line 
from R1-methanandamide and NAGly, increased cytotoxicity from arvanil.  These results 
demonstrated resistance to FAAH degradation isn’t as important as the inherent cytotoxicity of the 




 The COX-2/PGDS metabolic pathway was demonstrated to be vital to the anti-cancer 
activity of AEA in our system (Soliman et al. 2016a).  There are two characteristics important to 
COX-2 metabolism, overall ability to be metabolized by COX-2 and rate of metabolism.  All seven 
AEA analogs in the first-generation SAR study were hypothesized or have demonstrated COX-2 
metabolism, but the rates of COX-2 metabolism ranged from 40% that of AA with NAGly, to 
5.6% that of AA with arvanil, to unknown rates of metabolism (Prusakiewicz et al. 2007).  AEA 
is known to have a rate of metabolism 27% that of AA (Kozak et al. 2002).  We hypothesized that 
rates of metabolism, and in turn, concentrations of prostamide-D2 and prostamide-J2 played a role 
in the anti-cancer activity of AEA analogs.  This hypothesis was disproved by comparing 
cytotoxicity of AEA, NAGly, and arvanil.  Arvanil demonstrates the lowest rate of metabolism of 
the three, but demonstrates the greatest cytotoxicity.  This lends to the hypothesis that if the AEA 
analog can be metabolized by COX-2, then the most important aspect of the AEA analog is the 
inherent cytotoxicity of its J-series prostaglandin analogs which is determined by the modifications 
made to the ethanolamide region of AEA. 
  When considering inherent cytotoxicity of the COX-2/PGDS metabolized J-series 
prostaglandin analogs, we identified modifications that both enhance, retain, or decrease anti-
cancer activity.  Modifications to the terminal end group determined hydrogen bond accepting or 
donating capability is crucial, because AEA analogs in both the first and second generation that 
removed the terminal hydroxyl moiety or did not replace it with a carboxylate, AC and arvanil D2, 
lost all or most of their cytotoxicity.  Modifications that created a branched structure in the 
ethanolamide region, AS and ADA, dramatically reduced cytotoxicity.  Modifications that added 
little to dramatic steric bulk demonstrated mixed cytotoxic results, so we determined size of this 
region, as long as it does not interfere with COX-2 metabolism, has no significant role in anti-
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cancer activity.  Modifications that changed the distance between the amide bond and terminal 
group, A-Pro, arvanil, arvanil D1, arvanil D2, and AM404, produced mixed cytotoxicity results, 
demonstrating different chain lengths are permitted but there was no longer or shorter length trend 
apparent. 
These findings suggest a real opportunity to increase the anti-cancer activity and develop 
novel AEA and arvanil analog chemotherapeutics.  To aid in future studies and investigate the 
hypotheses and assumptions formed in this SAR study, two of the hit molecules, arvanil and 





Table 3.2: Cell Viability Results of Cytotoxicity SAR Study 
 
Green highlighted values represent the hit threshold set by AEA’s cytotoxicity.  Yellow highlighted values indicate 
that the cytotoxicity meets the hit threshold set forth by AEA’s cytotoxicity.                   
 
 
CHAPTER FOUR: ESTABLISHING CYTOTOXIC AND COX-2 
METABOLIC PROFILES OF NAGLY AND ARVANIL 
 
4.1: Design of Experiment Approach 
The AEA analog SAR study resulted in two hits, NAGly and arvanil, which were carried 
on to further studies.  This was done to explore their cytotoxic and metabolic profiles through the 
role of cannabinoid receptors, vanilloid receptors, COX-2, PGDS, and prostaglandin analog 
production.  Previous studies in our group demonstrated the role of COX-2 metabolism in the 
mechanism of AEA’s anti-cancer activity (Kuc et al. 2012, Soliman et al. 2016a).  By using a 
similar study, we can better identify how NAGly and arvanil are inducing cancer cell death and 
investigate the production of any novel D- and J-series prostaglandins.   
COX-2 metabolizes AEA to D- and J-series prostamides, which we have demonstrated is 
required for its anti-cancer activity in JWF2 cells.  Therefore, our goal was to determine the 
mechanism by which NAGly and arvanil were cytotoxic towards cancer cells.  Studies in this 
chapter will examine the role of the endocannabinoid system in the cytotoxicity of both molecules.  
Apoptosis, or programmed cell death, is vitally important for cellular processes including 
normal cell turnover and immune system development.  It is also the preferred method of cell death 
induced by chemotherapeutic agents.  Previous studies in our group determined that the 
cytotoxicity of both AEA and 15d-PMJ2 occurred via the apoptotic pathway (Soliman et al. 2016a, 
Soliman and Van Dross 2016b, Ladin et al. 2017).  Since this controlled cell death via apoptosis 
is preferred, our goal in Figure 4.4 was to investigate whether NAGly and arvanil induced COX-
2-dependent apoptotic cell death to establish their potential and their COX-2 metabolized J-series 
prostaglandin analogs as chemotherapeutics.  
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4.2: Concentration-Response Relationship Curve of AEA, NAGly, and Arvanil 
 The first step in establishing the cytotoxic profile of NAGly and arvanil is to compare their 
LC50’s to AEA.  To establish these LC50’s, we used the JWF2 NMSC cells because each molecule 
demonstrated maximum cytotoxicity at 20 µM in JWF2, but NAGly does not reach maximum 
cytotoxicity in HCA-7 cells.  Cells were treated with increasing concentration of AEA, NAGly, 
and arvanil on a logarithmic scale (Figure 4.1).  The LC50 data demonstrates AEA and NAGly 
have similar cytotoxicity in JWF2 cells, but arvanil has greater cytotoxicity and a correspondingly 
lower LC50.  This begins to establish a cytotoxic profile for arvanil that demonstrates it has the 
potential to be a more potent chemotherapeutic and produces more potent J-series prostaglandin 
analogs. The beginning of the cytotoxic profile for NAGly demonstrates an LC50 similar to AEA 
in JWF2 cells.  These results lead to a need for further studies to establish if NAGly or the J-series 






Figure 4.1: Concentration-Response Relationship Curve of AEA, NAGly, and Arvanil 
JWF2 NMSC cells were treated with varying concentrations of AEA, arvanil, and NAGly to determine a logarithmic 
dose response curve. Cell viability was evaluated by MTS assay according to manufacturer’s instructions. Data 





4.3: NAGly and Arvanil’s Cytotoxicity is CB1 and TRPV1 Receptor-independent 
AEA has demonstrated anti-cancer activity in CB1 and TRPV1 receptor-dependent 
mechanisms, yet other groups have demonstrated AEA’s anti-cancer activity is due to receptor-
independent mechanisms (Contassot et al. 2004, Melck et. al 2000, Melck et al. 1999, De 
Petrocellis et al. 1998, Kuc et al. 2012, Soliman and Van Dross 2016b).  Before investigating the 
COX-2 metabolism and metabolic products of arvanil and NAGly, we first wanted to examine if 
CB1 or TRPV1 receptors play a role in the anti-cancer activity of both molecules. To determine 
the role of the CB1-receptor and TRPV1-receptor in the anti-cancer activity of the AEA analogs, 
NAGly and arvanil, receptor antagonists, AM251 (CB1) and AMG9810 (TRPV1), were used to 
inhibit receptor-mediated activity.  
It was demonstrated that when JWF2 cells were treated with AEA analog and either 
AM251 or AMG9810, that the cells were not rescued from death, suggesting that the anti-cancer 
activity of arvanil and NAGly is CB1- and TRPV1 receptor-independent.  These data suggests that 
these pathways are not responsible for the anti-cancer activity observed with these three molecules 
in this cell line. 
 An interesting phenomenon was observed in HCA-7 colorectal cancer cells.  Arvanil’s 
anti-cancer activity is suggested to be CB1- and TRPV1 receptor-independent.  In HCA-7 cells 
that were treated with NAGly and AM251, an increase in cytotoxicity was observed in comparison 
to cells that were treated with NAGly alone.  Similarly, an increase in cytotoxicity occurred in 
cells treated with NAGly and AMG9810.  This suggests that inhibiting CB1 and TRPV1 receptor 
binding by NAGly, we can produce a stronger cytotoxic effect.  This could be attributed to the 
portion of the molecule that interacts with this receptor instead diverting to the COX-2 metabolic 
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Figure 4.2: NAGly and Arvanil’s Cytotoxicity is CB1 and TRPV1 Receptor-independent 
JWF2 NMSC cells and HCA-7 colorectal cancer cells were treated with 20 µM of arvanil, and NAGly with and 
without 1 µM of CB1 receptor antagonist, AM251, and with and without 1 µM of TRPV1 receptor antagonist, AMG 
9810. Cell viability was evaluated by MTS assay according to manufacturer’s instructions. Data represents mean ± 
SEM of three independent experiments and are expressed as percent viability compared to untreated cells. Data were 




4.4: AEA, NAGly, and Arvanil Produce D-series Prostaglandins and Prostamides 
 To begin investigation of the COX-2 and PGDS metabolism of arvanil and NAGly, using 
AEA as a positive control, we conducted an PGD2 ELISA assay with agent-treated media removed 
from JWF2 and HCA-7.  These results demonstrate, like AEA, NAGly and Arvanil are 
metabolized by COX-2 followed by PGDS producing D-series prostaglandin analogs, PGD2-
NAGly and PGD2-arvanil.  These findings are crucial in linking the anti-cancer activity produced 
by NAGly and arvanil to the COX-2 metabolic pathway.  Neither NAGly nor arvanil produced as 
high of a concentration of prostamide-D2 or prostamide-D2 analogs as AEA at 8 hours post 
treatment (Figure 4.3).  As mentioned earlier, the rate of metabolism of arvanil by COX-2 is 
reported to be lower than that of AEA.  This is important to note because arvanil’s anti-cancer 
activity is more powerful than AEA’s even though the concentration of PGD2-arvanil is lower than 
AEA.  This suggests PGD2-arvanil, once dehydrated to 15d-PGJ2-arvanil, produces stronger anti-





Figure 4.3: AEA, NAGly, and Arvanil Produce D-series Prostamides and Prostaglandin analogs 
JWF2 NMSC cells and HCA-7 colorectal cancer cells were treated with 20 µM of AEA, arvanil, and NAGly for 8 
hours.  PGD2, PMD2, and PMD2 analogs accumulated in the media were analyzed via ELISA analysis conducted via 
manufacturer’s instructions to measure D-series prostaglandins, prostamides, and prostaglandin analogs.  Data are 
represented by mean ± SEM and were analyzed using one-way ANOVA followed by Tukey’s analysis (P < 0.05 = *) 




4.5: Metabolism by COX-2 and PGDS is Required for Arvanil-induced Apoptotic Activity 
 We previously demonstrated AEA-induced apoptotic cell death is initiated via COX-2 
metabolism to D-series prostamides and ultimately, 15d-PMJ2 (Kuc et al. 2012, Soliman et al. 
2016a).  Caspase-3 and caspase-7 are known to be universally activated during apoptosis no matter 
the specific apoptotic cell death pathway (Luthi and Martin 2007, Timmer and Salvesen 2007). 
Using this information, we were able to use caspase-3/7 activity as a distinct marker for COX-2 
dependent apoptotic activity.   
In Figure 4.3, we demonstrated that arvanil and NAGly are metabolized by COX-2 and 
PGDS, producing D-series prostaglandin analogs.  In this experiment, we sought to determine if 
these D-series prostaglandin analogs were dehydrated to 15d-PMJ2-analogs which would suggest 
that these metabolites were responsible for the anti-cancer activity of arvanil and NAGly. To 
accomplish this, we used SeCl4, a PGDS inhibitor, to eliminate the production of D-series 
prostaglandin analogs and determine how this affected the anti-cancer activity of arvanil and 
NAGly.  Using AEA as a positive control, we were able to demonstrate that arvanil’s apoptotic 
anti-cancer activity is dependent upon the activity of PGDS (Figure 4.4).  These data suggest that 
arvanil is metabolized by COX-2 and PGDS to D-series prostaglandin analogs that are 
spontaneously dehydrated to J-series prostaglandin analogs. Hence these molecules may mediate 
the cytotoxicity of arvanil.  Mass spectrometry experiments, which are described in Figure 4.5, 




Figure 4.4: Metabolism by COX-2 and PGDS is Required for AEA and Arvanil-induced Apoptotic Activity 
HCA-7 colorectal cancer cells were treated with 100 µM of SeCl4, 20 µM of AEA, arvanil, NAGly and a combination 
of 100 µM SeCl4 and the three drugs. Caspase 3/7 activity was analyzed via Caspase Glo according to manufacturer’s 
instructions. Data represents mean ± SEM of three independent experiments and are expressed as percent viability 
compared to untreated cells. Data were analyzed using one-way ANOVA followed by Tukey’s analysis (P < 0.05 = 
*) when compared to vehicle treated cells. # represents statistically significant difference between the samples treated 





4.6: Mass Spectrometry Confirmation of 15d-PMJ2-arvanil Analog 
Throughout the studies exploring the mechanism of cell death, we determined that NAGly 
and arvanil follow the same metabolic pathway as AEA.  Because arvanil is more potent (Figure 
4.1) than both AEA and NAGly, and NAGly is not as efficacious in HCA-7 cells as AEA and 
arvanil (Figure 3.4), we decided to use LC-MS to investigate the presence of only 15d-PMJ2-
arvanil given the time- and resource-consuming nature of the experiments. 
LC-MS was conducted with lipid-extracted cell supernatant and we identified two peaks 
that contained m/z 450.278, the target m/z predicted for 15dPMJ2-arvanil.  As a result of in-source 
fragmentation, these peaks also contained m/z 270.965 and m/z 243.165, the m/z associated with 
common fragment ions associated with 15d-PMJ2, which are the same fragments that would be 
associated with 15d-PMJ2-arvanil.  It was interesting to identify two chromatographic peaks 
associated with the m/z of 15d-PMJ2-arvanil.  We theorize that a second peak could be associated 
with the COX-2/PGES metabolized 15d-PMA2-arvanil.  These two molecules would produce 
identical m/z, identical m/z fragments, but could differ slightly in retention time due to slightly 
differing polarities.  In prior studies, 15d-PMA2 was not identified and therefore its anti-cancer 
activity has not been characterized.  
These results confirmed the identification of a novel J-series prostamide, 15d-PMJ2-
arvanil, the end product of the COX-2, PGDS, and dehydration pathway.  In collaboration with 
the production of prostamide-D2 in arvanil-treated media established in figure 4.3 and the apoptotic 
activity data for arvanil established in Figure 4.4, we can suggest that arvanil’s anti-cancer activity 
is due to the production of this novel J-series prostamide-analog. These data provide a novel 
molecule to synthesize and carry out a cytotoxic profile study to determine its anti-cancer activity 





Figure 4.5: Mass Spectrometry Confirmation of 15d-PMJ2-arvanil Analog 
A. 15d-PMJ2-arvanil and common prostaglandin fragments.  B,C,D. LC-MS analysis was conducted on arvanil-treated 
HCA-7 colorectal cancer cell media to determine the production of 15d-PMJ2-arvanil.  Media was removed after 8 
hours of treatment and a solid phase lipid extraction was conducted.  LC-MS analysis was run on a SCIEX 425 
Eskigent/5600+ Triple TOF mass spectrometer analyzed using negative ionization mode.  Reverse phase LC was 





4.7: Conclusions of Cytotoxic and COX-2 Metabolic Profiles of Arvanil and NAGly 
 In this part of the study, the goal was to characterize the cytotoxic mechanism of arvanil 
and NAGly by determining the role of COX-2, PGDS, CB1 receptor, TRPV1 receptor, and the 
production of novel prostaglandin analogs in its activity.  In previous studies by our group, it was 
demonstrated that AEA’s anti-cancer activity in COX-2 overexpressing JWF2 was attributed to its 
metabolism by COX-2 and PGDS to 15d-PMJ2 (Van Dross 2009, Kuc et al. 2012). Using these 
same study guidelines, we conducted a study to investigate the mechanism of arvanil and NAGly’s 
cytotoxicity with a particular focus on its dependence of COX-2 and PGDS.  
 To compare the activity of AEA with arvanil and NAGly, a concentration-response 
experiment was conducted.  The results demonstrated that arvanil’s was more potent (LC50 = 6.03 
μM) than both AEA (LC50 = 9.39 μM) and NAGly (LC50 = 9.54 μM) (Figure 4.1).  Next, we 
determined if the activity of arvanil and NAGly were dependent on cannabinoid receptors.  The 
data suggested that the anti-cancer activity of both arvanil and NAGly were independent of the 
CB1 and TRPV1 receptors in JWF2 and HCA-7 cells (Figure 4.2).  This indicates that these 
receptors have no role in their anti-cancer activity. 
 To determine the role of COX-2 and PGDS metabolism, studies were completed to 
examine the production of PMD2 and J-series prostaglandin analogs.  The results demonstrated 
both, arvanil and NAGly, are metabolized by PGDS to PMD2-arvanil and PMD2-Gly (Figure 4.3).    
It has been demonstrated that AEA is metabolized by COX-2 and PGDS to PMD2 and 
spontaneously dehydrated to 15d-PMJ2, which is mainly responsible for its anti-cancer activity.  In 
addition, both arvanil and NAGly J-series prostaglandin-analogs were produced. Furthermore, 
these results demonstrated that blockade of PGDS, which prevents production of PMD2-arvanil, 
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PMJ2-arvanil, PMD2-Gly, and PMJ2-Gly, inhibits the apoptosis mediated by arvanil and NAGly 
(Figure 4.4). 
Since arvanil demonstrated it is the most cytotoxic hit throughout the SAR study, it is 
metabolized by COX-2 and PGDS, and its apoptotic anti-cancer activity was COX-2 and PGDS 
metabolism-dependent, we identified it has the greatest potential to produce novel J-series 
prostamide-analogs.  To investigate the production of these novel J-series prostamide-analogs, we 
conducted LC-MS analysis with arvanil-treated media.  The results of this analysis demonstrated 
the production of the novel J-series prostamide-analog, 15d-PMJ2-arvanil
 
 
CHAPTER FIVE: REVIEW OF MAJOR FINDINGS AND DISCUSSION 
Ten structurally modified AEA analogs were designed with the intent to decipher how each 
structural modification affected cytotoxicity.  We identified four parameters of our model system 
that could affect the anti-cancer activity of AEA analogs, (1) inherent cytotoxicity of J-series 
prostaglandin analogs, (2) COX-2 metabolism, (3) PGDS metabolism, and (4) FAAH degradation 
resistance.  Modifications made to the molecule to explore these parameters were part of one of 
the following groups; branching along the carbon chain, alteration of the hydrogen-bonding ability 
at the chain terminus, and addition of an aryl ring (Table 3.1).  Results and analysis from the SAR 
revealed the inherent cytotoxicity of the J-series prostaglandin analogs has the biggest role in the 
anti-cancer activity of AEA analogs (Table 3.2).  Two hits, arvanil (Figure 3.5) and NAGly (Figure 
3.3), were carried on to more in-depth analysis of their COX-2/PGDS metabolism and the role it 
has in their respective anti-cancer activity as well as the identification of novel 15d-PMJ2-arvanil 
by COX-2 metabolism of arvanil, the greatest cytotoxic AEA analog.   
The first parameter tested for its importance to cytotoxic activity was the hydrolase activity 
of FAAH, specifically the reduction in cytotoxicity of AEA due to rapid degradation by FAAH.  
It has been previously reported that blockade of FAAH’s hydrolase activity increases cytotoxicity 
of AEA (Kuc et al. 2012).  R1-methanandamide has demonstrated activity in vivo for long periods 
of time lending to its metabolic stability (Romero et al. 1996).  To test the role of FAAH in our 
model system the FAAH-resistant AEA analog, R1-methanandamide, was the first AEA analog 
investigated for its cytotoxicity compared to AEA. R1-methanandamide demonstrates a slight 
increase at 10 µM concentrations in JWF2 compared to AEA, but we don’t see increased 
cytotoxicity in HCA-7 (Figure 3.3).  R1-methanandamide adds steric bulk at the α-carbon of the 
ethanolamine, which is adjacent to the hydrolyzed amide bond, and this dramatically reduces the 
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hydrolase activity of FAAH, so we believed that adding any steric bulk at this carbon or even to 
the amide bond itself with the AEA analogs ADA and AS would also block FAAH’s hydrolase 
activity (Abadji et al. 1994).  Without specifically investigating the FAAH metabolism of ADA 
and AS, we relied on the cytotoxicity results to suggest if they were resisting degradation.  Since 
these two molecules weren’t cytotoxic, we couldn’t decipher if they resist FAAH degradation or 
if their COX-2 metabolized J-series prostaglandin analogs aren’t as cytotoxic.  It has been reported 
amides of propanolamine’s three-carbon chain or higher were hydrolyzed by FAAH at reduced 
rates compared to ethanolamine (Schmid et al. 1985).  We assumed any AEA analog with three 
carbons or more between the amide bond and the terminal end moiety, A-Pro, arvanil, AM404, 
arvanil D1, arvanil D2 would resist hydrolase activity of FAAH or dramatically lower the rate of 
degradation.  Through all these modifications to resist FAAH degradation, we believed we could 
decipher if FAAH was playing the most important role in our model system.  Of the molecules 
believed to resist FAAH’s hydrolase activity, R1-methanandamide (Figure 3.3), A-Pro (Figure 
3.7), ADA (Figure 3.6), AS (Figure 3.8), AM404 (Figure 3.10), and arvanil D2 (Figure 3.12) have 
no anti-cancer activity or reduced cytotoxicity compared to that of AEA, but arvanil (Figure 3.5) 
and arvanil D1 (Figure 3.11) have increased cytotoxicity.  These results suggested FAAH, 
specifically resistance to FAAH’s hydrolase activity, doesn’t have the most important role in the 
anti-cancer activity of AEA analogs. 
Another focus of our original hypotheses was the metabolic activity of COX-2, including 
the rate of metabolism of AEA analogs.  All AEA analogs, except for AM404, were designed or 
known to retain the COX-2 metabolism of AEA, by not making modification on the 20-carbon 
chain backbone of AEA, but their rates of metabolism differed (Prusakiewicz et al. 2007, Dietz et 
al. 1988, Hamberg and Samuelsson 1967, Hogestatt et al. 2005). We predicted molecules that have 
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a higher rate of COX-2 metabolism, and in turn produce a higher concentration of J-series 
prostaglandin analogs, would have increased cytotoxicity compared to that of AEA.  This theory 
was disproved by a comparison of NAGly and arvanil.  NAGly has a COX-2 rate of metabolism 
40% that of AA and arvanil exhibits the lowest rate of COX-2 metabolism, 5.6% that of AA, yet 
arvanil demonstrated the greatest cytotoxicity (Figure 3.5) due to its COX-2/PGDS metabolism 
(Figure 4.4) and subsequent production of D-series prostaglandin analogs (Figure 4.3) and 15d-
PMJ2-arvanil (Figure 4.5) (Prusakiewicz et al. 2007).  Further investigation of the correlation 
between COX-2 rates of metabolism and anti-cancer activity should have produced a relationship 
based on production of prostamide-D2 and prostamide-D2 analogs. NAGly has the highest COX-
2 metabolism rate of any AEA analog but didn’t lead to a dramatically greater concentration of 
PGD2 analogs compared to AEA, which has a COX-2 metabolism rate 27% that of AA, or arvanil, 
which has a COX-2 metabolism rate 5.6% that of AA (Prusakiewicz et al. 2007, Kozak et al. 2002) 
(Figure 4.3).  These results indicate there is no relationship between rate of COX-2 metabolism 
and cytotoxicity of AEA analogs and continues to demonstrate the inherent cytotoxicity of the J-
series prostaglandin analogs play the most important role in the overall anti-cancer activity. 
 Previously, it has been reported that arvanil demonstrates anti-invasive activity towards 
small cell lung cancers mediated by the AMPK pathway and induces apoptosis in Jurkat cells 
through an FADD/caspase-8-dependent pathways (Hurley et al. 2016, Sancho et al. 2003).  In our 
studies, we suggest arvanil’s anti-cancer activity is attributed to its COX-2/PGDS metabolism and 
subsequent dehydrations to 15d-PMJ2-arvanil.  The requirement of this activity is the COX-2 
overexpression in our model cell lines, but in future studies 15d-PMJ2-arvanil will be synthesized 
and investigated for its COX-2 independent cytotoxicity in a variety of cancers. 
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 The cytotoxicity results from the SAR study (Table 3.2), in comparison with the PGD2 
production (Figure 4.3), lead us to believe this system is more complex than we originally thought.  
When developing a pro-drug all receptors and enzymes that have interactions with the molecule 
can play a role in its intended activity.  As shown in Scheme 1.1, after AA, AEA, and other AEA 
analogs are metabolized by COX-2 there are multiple prostaglandin synthases that can metabolize 
PGH2, PMH2, and PMH2 analogs to different series of prostaglandins, prostamides, and 
prostaglandin analogs.  We have demonstrated previously and in this study the COX-2/PGDS 
metabolism is responsible for the anti-cancer activity of AEA and AEA analogs (Soliman et al. 
2016a).  On the other hand, COX-2/PGES metabolism of AA to E-series prostaglandins has been 
shown to be responsible for tumor growth in skin cancer and colon cancer (Ansari et al. 2008, Pai 
et al. 2002).   Metabolism preferences by PGES and PGDS compared to AEA were not explored.  
If these differences lead to a higher concentration of PME2 analogs compared to AEA, then not 
only could this be responsible for less than expected concentrations of PMD2, but it could be 
responsible for the decreased apoptotic activity and cytotoxicity in HCA-7 cells demonstrated by 
NAGly for example.  Without knowing the concentrations of PME2-NAGly compared to PMD2-
NAGly we can’t suggest bias for specific prostaglandin synthases is responsible for the reduced 
production of D-series prostaglandin analogs, but future studies can investigate this theory.  
 We set forth to improve on the chemotherapeutic activity of the endocannabinoid AEA and 
its COX-2/PGDS metabolized 15d-PMJ2.  To accomplish this a SAR study and follow up studies 
to identify cytotoxic and COX-2 metabolic profiles of the two most promising hits were conducted.  
With the results from two generations of a SAR study, we were able to identify two hits with 
increased or similar cytotoxicity in COX-2 overexpressing cancer cells, NAGly and arvanil.  
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Through investigation of its COX-2 metabolic profile and its apoptotic anti-cancer activity, NAGly 
didn’t demonstrate potential as an improved chemotherapeutic.   
 PGA2 has shown anti-proliferation effects in esophageal cancer cells and an increase in 
total tyrosine kinase activity (Joubert et al. 1999).  In RKO rectal carcinoma cells, PGA2 induces 
cell death correlated with a lack of cyclin-dependent kinase inhibitor p21 (Gorospe and Holbrook 
1996).  In Figure 4.5, we identified two distinct peaks correlated with the target m/z of 15d-PMJ2-
arvanil and associated fragments.  This phenomenon hasn’t occurred in our previous studies 
identifying 15d-PMJ2, leading us to believe these peaks are associated with two different 
molecules, 15d-PMA2-arvanil and 15d-PMJ2-arvanil.  We theorize both of these molecules are 
present in arvanil-treated media and the production of 15d-PMA2-arvanil could be playing a role 
in the increased cytotoxicity of arvanil, although Figure 4.4 suggested 15d-PMJ2-arvanil is 
responsible for the entirety of the apoptotic cell death associated with arvanil.  Future studies to 
confirm the production of 15d-PMA2-arvanil and its role in cytotoxicity will be pursued. 
We were the first to identify arvanil’s J-series prostamide, 15d-PMJ2-arvanil, and suggest 
its contribution to its apoptotic anti-cancer activity.  To further demonstrate 15d-PMJ2-arvanil’s 
anti-cancer activity, it will be synthesized using the synthetic techniques set forth previously by 
our group (Ladin et al. 2017).  Once synthesized, 15d-PMJ2-arvanil’s cytotoxic profile will be 
investigated to determine its potential as a novel chemotherapeutic.
   
 
FUTURE DIRECTIONS 
 In this study we provided evidence of a novel COX-2 metabolized J-series prostaglandin 
analog, 15d-PMJ2-arvanil, identified via LC-MS.  This metabolite was a product of the COX-
2/PGDS metabolism of arvanil, which demonstrated increased COX-2 dependent apoptotic anti-
cancer activity compared to that of AEA.  In previous studies, our group has characterized the 
anti-cancer activity of 15d-PMJ2, the novel J-series prostamide metabolite of AEA, and 
demonstrated its powerful selective toxicity in a variety of cancer cell lines as well as in vivo.  
These studies have laid out an experimental roadmap for future studies of novel J-series 
prostamide chemotherapeutics, such as 15d-PMJ2-arvanil.  Using an identical synthetic route to 
produce various AEA analogs in this study as well as 15d-PMJ2 in previous studies by Ladin et 
al., we will synthesize and characterize 15d-PMJ2-arvanil (Figure 5.1) (Ladin et al. 2017). Once 
synthesized, 15d-PMJ2-arvanil’s selective chemotherapeutic potential will be investigated via 
cytotoxicity experiments in various cancer cell lines including NMSC, colorectal cancer, 
melanoma, and corresponding nontumorigenic cell lines.  If its selective toxicity is established 
and its chemotherapeutic potential is similar or greater than 15d-PMJ2, we will perform studies to 
investigate its mechanism of cell death, including its induction of apoptosis and whether it is 
inducing ER-stress mediated cell death which is the cell death pathway identified for 15d-PMJ2. 
 As demonstrated in Figure 4.5, we identified a potential second metabolite with identical 
m/z and fragmentation pattern as 15d-PMJ2-arvanil.  We hypothesize this peak and its associated 
ion fragments are produced by the A-series metabolite, 15d-PMA2-arvanil.  To test this 
hypothesis, we will conduct a PGDS inhibition experiment identical to the Figure 4.4 and 
perform LC-MS on the lipid extracted media.  If we observe a disappearance of both peaks it 
would disprove our theory of A-series metabolite production, and if we observe a disappearance 
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of only one peak it would suggest our theory is correct.  If the latter comes to fruition, we would 
then synthesize this A-series metabolite, 15d-PMA2-arvanil and establish if it is cytotoxic on its 




Figure 5.1: Proposed Synthesis of 15d-PMJ2-arvanil from 15d-PGJ2
   
 
SUPPLEMENTARY FIGURES A: SYNTHESIS AND 
CHARACTERIZATION OF AEA ANALOGS 
 
Figure A.1: Synthesis and Characterization of Arachidonoyl Propanolamine (A-Pro) 
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